Cargando…
Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
BACKGROUND: Cost utility analysis (CUA) using SF-36/SF-12 data has been facilitated by the development of several preference-based algorithms. The purpose of this study was to illustrate how decision-making could be affected by the choice of preference-based algorithms for the SF-36 and SF-12, and p...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC555748/ https://www.ncbi.nlm.nih.gov/pubmed/15748287 http://dx.doi.org/10.1186/1477-7525-3-11 |
_version_ | 1782122554519977984 |
---|---|
author | Pickard, A Simon Wang, Zhixiao Walton, Surrey M Lee, Todd A |
author_facet | Pickard, A Simon Wang, Zhixiao Walton, Surrey M Lee, Todd A |
author_sort | Pickard, A Simon |
collection | PubMed |
description | BACKGROUND: Cost utility analysis (CUA) using SF-36/SF-12 data has been facilitated by the development of several preference-based algorithms. The purpose of this study was to illustrate how decision-making could be affected by the choice of preference-based algorithms for the SF-36 and SF-12, and provide some guidance on selecting an appropriate algorithm. METHODS: Two sets of data were used: (1) a clinical trial of adult asthma patients; and (2) a longitudinal study of post-stroke patients. Incremental costs were assumed to be $2000 per year over standard treatment, and QALY gains realized over a 1-year period. Ten published algorithms were identified, denoted by first author: Brazier (SF-36), Brazier (SF-12), Shmueli, Fryback, Lundberg, Nichol, Franks (3 algorithms), and Lawrence. Incremental cost-utility ratios (ICURs) for each algorithm, stated in dollars per quality-adjusted life year ($/QALY), were ranked and compared between datasets. RESULTS: In the asthma patients, estimated ICURs ranged from Lawrence's SF-12 algorithm at $30,769/QALY (95% CI: 26,316 to 36,697) to Brazier's SF-36 algorithm at $63,492/QALY (95% CI: 48,780 to 83,333). ICURs for the stroke cohort varied slightly more dramatically. The MEPS-based algorithm by Franks et al. provided the lowest ICUR at $27,972/QALY (95% CI: 20,942 to 41,667). The Fryback and Shmueli algorithms provided ICURs that were greater than $50,000/QALY and did not have confidence intervals that overlapped with most of the other algorithms. The ICUR-based ranking of algorithms was strongly correlated between the asthma and stroke datasets (r = 0.60). CONCLUSION: SF-36/SF-12 preference-based algorithms produced a wide range of ICURs that could potentially lead to different reimbursement decisions. Brazier's SF-36 and SF-12 algorithms have a strong methodological and theoretical basis and tended to generate relatively higher ICUR estimates, considerations that support a preference for these algorithms over the alternatives. The "second-generation" algorithms developed from scores mapped from other indirect preference-based measures tended to generate lower ICURs that would promote greater adoption of new technology. There remains a need for an SF-36/SF-12 preference-based algorithm based on the US general population that has strong theoretical and methodological foundations. |
format | Text |
id | pubmed-555748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-5557482005-04-01 Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? Pickard, A Simon Wang, Zhixiao Walton, Surrey M Lee, Todd A Health Qual Life Outcomes Research BACKGROUND: Cost utility analysis (CUA) using SF-36/SF-12 data has been facilitated by the development of several preference-based algorithms. The purpose of this study was to illustrate how decision-making could be affected by the choice of preference-based algorithms for the SF-36 and SF-12, and provide some guidance on selecting an appropriate algorithm. METHODS: Two sets of data were used: (1) a clinical trial of adult asthma patients; and (2) a longitudinal study of post-stroke patients. Incremental costs were assumed to be $2000 per year over standard treatment, and QALY gains realized over a 1-year period. Ten published algorithms were identified, denoted by first author: Brazier (SF-36), Brazier (SF-12), Shmueli, Fryback, Lundberg, Nichol, Franks (3 algorithms), and Lawrence. Incremental cost-utility ratios (ICURs) for each algorithm, stated in dollars per quality-adjusted life year ($/QALY), were ranked and compared between datasets. RESULTS: In the asthma patients, estimated ICURs ranged from Lawrence's SF-12 algorithm at $30,769/QALY (95% CI: 26,316 to 36,697) to Brazier's SF-36 algorithm at $63,492/QALY (95% CI: 48,780 to 83,333). ICURs for the stroke cohort varied slightly more dramatically. The MEPS-based algorithm by Franks et al. provided the lowest ICUR at $27,972/QALY (95% CI: 20,942 to 41,667). The Fryback and Shmueli algorithms provided ICURs that were greater than $50,000/QALY and did not have confidence intervals that overlapped with most of the other algorithms. The ICUR-based ranking of algorithms was strongly correlated between the asthma and stroke datasets (r = 0.60). CONCLUSION: SF-36/SF-12 preference-based algorithms produced a wide range of ICURs that could potentially lead to different reimbursement decisions. Brazier's SF-36 and SF-12 algorithms have a strong methodological and theoretical basis and tended to generate relatively higher ICUR estimates, considerations that support a preference for these algorithms over the alternatives. The "second-generation" algorithms developed from scores mapped from other indirect preference-based measures tended to generate lower ICURs that would promote greater adoption of new technology. There remains a need for an SF-36/SF-12 preference-based algorithm based on the US general population that has strong theoretical and methodological foundations. BioMed Central 2005-03-04 /pmc/articles/PMC555748/ /pubmed/15748287 http://dx.doi.org/10.1186/1477-7525-3-11 Text en Copyright © 2005 Pickard et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Pickard, A Simon Wang, Zhixiao Walton, Surrey M Lee, Todd A Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? |
title | Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? |
title_full | Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? |
title_fullStr | Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? |
title_full_unstemmed | Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? |
title_short | Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? |
title_sort | are decisions using cost-utility analyses robust to choice of sf-36/sf-12 preference-based algorithm? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC555748/ https://www.ncbi.nlm.nih.gov/pubmed/15748287 http://dx.doi.org/10.1186/1477-7525-3-11 |
work_keys_str_mv | AT pickardasimon aredecisionsusingcostutilityanalysesrobusttochoiceofsf36sf12preferencebasedalgorithm AT wangzhixiao aredecisionsusingcostutilityanalysesrobusttochoiceofsf36sf12preferencebasedalgorithm AT waltonsurreym aredecisionsusingcostutilityanalysesrobusttochoiceofsf36sf12preferencebasedalgorithm AT leetodda aredecisionsusingcostutilityanalysesrobusttochoiceofsf36sf12preferencebasedalgorithm |